Background
Gilead Sciences develops and sells prescription drugs, including the HIV medication Biktarvy, in domestic and foreign markets. After a Maryland patient received Turkish-market Biktarvy through his employer’s self-funded health plan, Gilead investigated and found that Rx Valet, Advanced Pharmacy, Affordable RX Meds, and Gregory Santulli had arranged for hundreds of bottles of foreign-market Gilead medications to be shipped to patients in the United States. Although the Turkish Biktarvy was manufactured with Gilead’s authorization and chemically identical to the U.S. version, its labeling and patient information were in Turkish and omitted warnings and other information accompanying the domestic product.
Gilead sued the four direct participants, along with third-party administrator Meritain Health and pharmacy benefit manager ProAct, under the Lanham Act. It alleged that the direct participants infringed Gilead’s marks by importing and distributing materially different foreign-market drugs and that Meritain and ProAct contributorily infringed by continuing to provide services facilitating the program. The district court entered a preliminary injunction barring the defendants from importing, advertising, selling, or facilitating the importation of products bearing specified Gilead marks. The defendants appealed.
The Court’s Holding
The Fourth Circuit affirmed. It held that Gilead was likely to prove direct trademark infringement because the imported medications were not genuine goods for Lanham Act purposes. Despite having the same chemical formulation as their U.S. counterparts, the foreign-market drugs materially differed in labeling, warnings, identifying information, and regulatory materials. They also bypassed Gilead’s domestic quality-control system, including temperature monitoring, chain-of-custody documentation, recall procedures, and its closed distribution network. Those differences supported a likelihood of consumer confusion, and the first-sale doctrine therefore did not bar Gilead’s claims.
The court also held that Gilead was likely to establish contributory infringement by Meritain and ProAct. The evidence supported findings that both continued supplying services to identified participants in the importation program while knowing or having reason to know that the foreign-market drugs were materially different and infringing. The court rejected the argument that prior specific notice from the trademark owner was required and declined to add “degree of control” as a separate element of contributory infringement. It further held that the Food, Drug, and Cosmetic Act did not preclude Gilead’s claims because the Lanham Act analysis did not require determining whether the imported drugs violated federal drug law.
Finally, the court found no abuse of discretion in the district court’s treatment of the remaining preliminary-injunction factors. Gilead’s investigation and referral of the matter to the FDA adequately explained the ten months between learning of the patient’s experience and filing suit, so the delay did not defeat irreparable harm. The balance of equities and public interest also favored an injunction. The court declined to exercise pendent appellate jurisdiction over the denial of Santulli’s motion to dismiss for lack of personal jurisdiction and held that he had not preserved his separate argument concerning the jurisdictional showing required for preliminary relief.
Key Takeaways
- Authentic gray-market goods may still be non-genuine under the Lanham Act when they materially differ from authorized domestic goods or bypass the trademark owner’s legitimate quality controls.
- Chemical identity does not eliminate material differences in prescription drugs when labeling, safety warnings, regulatory information, distribution safeguards, or recall protections differ.
- Contributory infringement does not require prior specific notice from the trademark owner; knowledge, reason to know, or willful blindness may satisfy the knowledge requirement.
Why It Matters
The decision applies the material-differences doctrine to gray-market prescription drugs in the Fourth Circuit and confirms that labeling, safety information, traceability, transportation controls, and recall procedures can determine whether a product is genuine for trademark purposes. Businesses cannot avoid infringement merely by showing that an imported drug is authentic and chemically identical to the domestic version.
The opinion also clarifies secondary trademark liability for service providers in the circuit. Administrators and benefit managers that knowingly continue supplying data, referrals, claims processing, or payment services to identified infringers may face contributory liability without receiving a cease-and-desist letter and without satisfying a separate control-over-the-infringement test.